Last reviewed · How we verify

NCT02885597

Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials

Status unknown Phase 2/Phase 3 Last updated 13 July 2018
What this trial tests

Phase 2/Phase 3 trial testing Juanbi pill in Juanbi Pill in 120 participants. Status unknown.

Timeline
1 July 2018
Primary endpoint
1 December 2018
1 December 2020

Quick facts

Lead sponsorCui xuejun
PhasePhase 2/Phase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment120
Start date1 July 2018
Primary completion1 December 2018
Estimated completion1 December 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Cui xuejun — full company profile →

Who can join

Adults 18 to 80, any sex, with Juanbi Pill or Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine whether Juanbi Pill combined with methotrexate are effective in the treatment of active Rheumatoid Arthritis (RA).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.
    Wang Q, Wang YR, Jia QY, Liu L, et al · · 2018 · cited 12× · PMID 29558967 · DOI 10.1186/s13063-018-2555-1
  2. Efficacy and Safety of Juan Bi Pill with Add-on Methotrexate in Active Rheumatoid Arthritis: A 48-Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jia QY, Wang YR, Sun DW, Mao JC, et al · · 2025 · cited 1× · PMID 39707138 · DOI 10.1007/s11655-024-3768-7
  3. Efficacy and Safety of the Juan Bi Pill Combined with Methotrexate for Treating Active Rheumatoid Arthritis
    Jia Q, Wang Y, Sun D, Li Q, et al · · 2022 · DOI 10.21203/rs.3.rs-1980301/v1

Verify or expand the search:

Other Cui xuejun trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02885597.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing